undamentalytics Newsletter
Sign in

IQVIA revenue

IQVIA's revenue was $16.31bn in fiscal 2025, up 5.9% on the year before. Since fiscal 2011 ($4.33bn) it has grown at a compound 9.9% a year. Over the last twelve months it was $17.31bn.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue4.34.95.15.55.76.99.710.411.111.413.914.415.015.416.317.3
Growth on the year before—+12.4%+4.8%+7.1%+5.1%+19.9%+41.6%+6.9%+6.5%+2.4%+22.1%+3.9%+4.0%+2.8%+5.9%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Research and Development Solutions $8.9B 54.5% ▲ 4.3%
Technology and Analytics Solutions $6.6B 40.6% ▲ 7.6%
Contract Sales and Medical Solutions $788M 4.8% ▲ 9.7%
Geography
Region Revenue Share YoY
Americas $7.7B 47.5% ▲ 5.3%
EMEA $5.2B 31.8% ▲ 5.4%
Asia Pacific $3.4B 20.7% ▲ 8.0%

From IQVIA's 10-K filed February 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
IQVIA $17.31bn 8.8% 5.2%
Danaher Corporation $25.61bn 5.5% 1.3%
Icon PLC $8.25bn 0.8% 83.5%
Agilent Technologies $7.37bn 8.6% 1.8%
Avantor, Inc. $6.64bn 0.9% -1.9%
Thermo Fisher Scientific $47.35bn 8.3% 2.9%

Compare with peers

Head to head: DHR vs IQVICLR vs IQVA vs IQVIQV vs TMO

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from IQVIA's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to IQVIA.